Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development [Yahoo! Finance]
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... [Yahoo! Finance]
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript [Seeking Alpha]